G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus

Pharmacological Reviews

Volumn 70, Issue 1, 2018, Pages 39-67

  Riddy, Darren M ^a   Delerive, Philippe ^b   Summers, Roger J ^a   Sexton, Patrick M ^a   Langmead, Christopher J ^a  

^a MONASH UNIVERSITY   (Australia)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CHEMOKINE RECEPTOR CCR2; ESTROGEN RECEPTOR; FATTY ACID; FREE FATTY ACID RECEPTOR 2; FREE FATTY ACID RECEPTOR 3; G PROTEIN COUPLED ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 120; G PROTEIN COUPLED RECEPTOR 142; G PROTEIN COUPLED RECEPTOR 21; G PROTEIN COUPLED RECEPTOR 35; G PROTEIN COUPLED RECEPTOR 40; G PROTEIN COUPLED RECEPTOR 41; G PROTEIN COUPLED RECEPTOR 43; G PROTEIN COUPLED RECEPTOR 55; G PROTEIN COUPLED RECEPTOR 82; G PROTEIN COUPLED RECEPTOR 84; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GPRC5B PROTEIN; HYDROXYCARBOXYLIC ACID RECEPTOR 2; LEUKOTRIENE B4; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PROSTAGLANDIN E RECEPTOR 3; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS FUNCTION DISORDER; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; MOLECULAR TARGETED THERAPY; OBESITY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85040020831     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.117.014373     Document Type: Review

References (360)

1. Abbracchio MP, Boeynaems J-M, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, King BF, Gachet C, Jacobson KA, Weisman GA, et al. (2003) Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 24:52-55.
2. Abdel-Magid AF (2015) Prostaglandin EP3 receptor antagonists may provide novel treatment for diabetes. ACS Med Chem Lett 6:626-627.
3. Ahmed K, Tunaru S, Langhans C-D, Hanson J, Michalski CW, Kölker S, Jones PM, Okun JG, and Offermanns S (2009) Deorphanization of GPR109B as a receptor for the b-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem 284:21928-21933.
4. Ahrén B (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8:369-385.
5. Ahrén B, Holst JJ, and Efendic S (2000) Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab 85:1043-1048.
6. Al-Barazanji K, McNulty J, Binz J, Generaux C, Benson W, Young A, and Chen L (2015) Synergistic effects of a GPR119 agonist with metformin on weight loss in diet-induced obese mice. J Pharmacol Exp Ther 353:496-504.
7. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, et al.; CGTP Collaborators (2015) The concise guide to pharmacology 2015/16: overview. Br J Pharmacol 172:5729-5743.
8. Alvarez-Curto E, Inoue A, Jenkins L, Raihan SZ, Prihandoko R, Tobin AB, and Milligan G (2016) Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signaling. J Biol Chem 291:27147-27159.
9. Alvarez-Curto E and Milligan G (2016) Metabolism meets immunity: the role of free fatty acid receptors in the immune system. Biochem Pharmacol 114:3-13.
10. Arch JR (2002) beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440:99-107.
11. Arch JR (2008) The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 378:225-240.
12. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, and Wilson S (1984) Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309:163-165.
13. Audoy-Rémus J, Bozoyan L, Dumas A, Filali M, Lecours C, Lacroix S, Rivest S, Tremblay ME, and Vallières L (2015) GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer’s disease. Brain Behav Immun 46:112-120.
14. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S, Klussmann S, Eulberg D, Luedde T, et al. (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416-426.
15. Baggio LL and Drucker DJ (2014) Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest 124:4223-4226.
16. Balhuizen A, Kumar R, Amisten S, Lundquist I, and Salehi A (2010) Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol 320:16-24.
17. Beak J, Huang W, Parker JS, Hicks ST, Patterson C, Simpson PC, Ma A, Jin J, and Jensen BC (2017) An oral selective alpha-1A adrenergic receptor agonist prevents doxorubicin cardiotoxicity. JACC Basic Transl Sci 2:39-53.
18. Berchiche YA, Gravel S, Pelletier M-E, St-Onge G, and Heveker N (2011) Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, Gai signaling, and receptor internalization. Mol Pharmacol 79: 488-498.
19. Bindels LB, Dewulf EM, and Delzenne NM (2013) GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol Sci 34:226-232.
20. Bjursell M, Admyre T, Göransson M, Marley AE, Smith DM, Oscarsson J, and Bohlooly Y M (2011) Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 300:E211-E220.
21. Blad CC, Tang C, and Offermanns S (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov 11:603-619.
22. Blodgett DM, Nowosielska A, Afik S, Pechhold S, Cura AJ, Kennedy NJ, Kim S, Kucukural A, Davis RJ, Kent SC, et al. (2015) Novel observations from nextgeneration RNA sequencing of highly purified human adult and fetal islet cell subsets. Diabetes 64:3172-3181.
23. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, and Hjerpsted JB (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19:1242-1251
24. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207-212.
25. Bolognini D, Moss CE, Nilsson K, Petersson AU, Donnelly I, Sergeev E, König GM, Kostenis E, Kurowska-Stolarska M, Miller A, et al. (2016) A novel allosteric activator of free fatty acid 2 receptor displays unique gi-functional bias. J Biol Chem 291:18915-18931.
26. Bonnefond A, Clément N, Fawcett K, Yengo L, Vaillant E, Guillaume J-L, Dechaume A, Payne F, Roussel R, Czernichow S, et al.; Meta-Analysis of Glucose and Insulin- Related Traits Consortium (MAGIC) (2012) Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 44: 297-301.
27. Boring L, Gosling J, Chensue SW, Kunkel SL, Farese RV Jr, Broxmeyer HE, and Charo IF (1997) Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100: 2552-2561.
28. Boschmann M, Krupp G, Luft FC, Klaus S, and Jordan J (2002) In vivo response to alpha(1)-adrenoreceptor stimulation in human white adipose tissue. Obes Res 10: 555-558.
29. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, Sparsø T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, et al. (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89-94.
30. Bouchard C, Pagé J, Bédard A, Tremblay P, and Vallières L (2007) G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia 55:790-800.
31. Bresnick JN, Skynner HA, Chapman KL, Jack AD, Zamiara E, Negulescu P, Beaumont K, Patel S, and McAllister G (2003) Identification of signal transduction pathways used by orphan g protein-coupled receptors. Assay Drug Dev Technol 1:239-249.
32. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, Littleton TR, McCoy DC, Kenakin TP, Andrews JL, Ammala C, et al. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148:619-628.
33. Brothers SP and Wahlestedt C (2010) Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2:429-439.
34. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, et al. (2003) The orphan G proteincoupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312-11319.
35. Burant CF (2013) Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. Diabetes Care 36 (Suppl 2):S175-S179.
36. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, and Blonde L; LEAD-6 Study Group (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47.
37. Camell CD, Nguyen KY, Jurczak MJ, Christian BE, Shulman GI, Shadel GS, and Dixit VD (2015) Macrophage-specific de novo synthesis of ceramide is dispensable for inflammasome-driven inflammation and insulin resistance in obesity. J Biol Chem 290:29402-29413.
38. Cantini G, Mannucci E, and Luconi M (2016) Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol Metab 27:427-438.
39. Carmone C, Robben J, Ariza A, Bekkenkamp M, Kurstjens S, Devuyst O, and Deen P (2015) The succinate receptor 1 is a physiological regulator of the reninangiontensin aldosterone system. FASEB J 29.
40. Carter RL, Fricks IP, Barrett MO, Burianek LE, Zhou Y, Ko H, Das A, Jacobson KA, Lazarowski ER, and Harden TK (2009) Quantification of gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol 76:1341-1348.
41. Cattaneo M (2015) P2Y12 receptors: structure and function. J Thromb Haemost 13 (Suppl 1):S10-S16.
42. Cawthorne MA, Carroll MJ, Levy AL, Lister CA, Sennitt MV, Smith SA, and Young P (1984) Effects of novel beta-adrenoceptor agonists on carbohydrate metabolism: relevance for the treatment of non-insulin-dependent diabetes. Int J Obes 8 (Suppl 1):93-102.
43. Ceddia RP, Lee D, Maulis MF, Carboneau BA, Threadgill DW, Poffenberger G, Milne G, Boyd KL, Powers AC, McGuinness OP, et al. (2016) The PGE2 EP3 receptor regulates diet-induced adiposity in male mice. Endocrinology 157:220-232.
44. Cerf ME (2013) Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne) 4:37.
45. Chandra V, Karamitri A, Richards P, Cormier F, Ramond C, Jockers R, Armanet M, Albagli-Curiel O, and Scharfmann R (2016) Extracellular acidification stimulates GPR68 mediated IL-8 production in human pancreatic b cells. Sci Rep 6:25765.
46. Chao EC (2014) SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes 32:4-11.
47. Chawla A, Nguyen KD, and Goh YPS (2011) Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 11:738-749.
48. Chen T, Zheng X, Ma X, Bao Y, Ni Y, Hu C, Rajani C, Huang F, Zhao A, Jia W, et al. (2016) Tryptophan predicts the risk for future type 2 diabetes. PLoS One 11: e0162192.
49. Cheng C, Chiu HJ, Loh el-W, Chan CH, Hwu TM, Liu YR, and Lan TH (2012) Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 36:205-210.
50. Cheng JT, Liu IM, Yen ST, and Chen PC (2000) Role of alpha1A-adrenoceptor in the regulation of glucose uptake into white adipocyte of rats in vitro. Auton Neurosci 84:140-146.
51. Cheng S-B, Graeber CT, Quinn JA, and Filardo EJ (2011) Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 76:892-896.
52. Chorvat RJ (2013) Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett 23:4751-4760.
53. Chu CA, Sindelar DK, Igawa K, Sherck S, Neal DW, Emshwiller M, and Cherrington AD (2000) The direct effects of catecholamines on hepatic glucose production occur via alpha(1)- and beta(2)-receptors in the dog. Am J Physiol Endocrinol Metab 279: E463-E473.
54. Chu Z-L, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, et al. (2008) A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149:2038-2047.
55. Clemmensen C, Pehmøller C, Klein AB, Ratner C, Wojtaszewski JF, and Bräuner- Osborne H (2013a) Enhanced voluntary wheel running in GPRC6A receptor knockout mice. Physiol Behav 118:144-151.
56. Clemmensen C, Smajilovic S, Madsen AN, Klein AB, Holst B, and Bräuner-Osborne H (2013b) Increased susceptibility to diet-induced obesity in GPRC6A receptor knockout mice. J Endocrinol 217:151-160.
57. Cohen LJ, Kang H-S, Chu J, Huang Y-H, Gordon EA, Reddy BVB, Ternei MA, Craig JW, and Brady SF (2015) Functional metagenomic discovery of bacterial effectors in the human microbiome and isolation of commendamide, a GPCR G2A/132 agonist. Proc Natl Acad Sci USA 112:E4825-E4834.
58. Cooper ME (2012) Diabetes: treating diabetic nephropathy: still an unresolved issue. Nat Rev Endocrinol 8:515-516.
59. Corrêa-Oliveira R, Fachi JL, Vieira A, Sato FT, and Vinolo MAR (2016) Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunology 5:e73.
60. Costes S, Boss M, Thomas AP, and Matveyenko AV (2015) Activation of melatonin signaling promotes b-cell survival and function. Mol Endocrinol 29:682-692.
61. Cranford TL, Enos RT, Velázquez KT, McClellan JL, Davis JM, Singh UP, Nagarkatti M, Nagarkatti PS, Robinson CM, and Murphy EA (2016) Role of MCP-1 on inflammatory processes and metabolic dysfunction following high-fat feedings in the FVB/N strain. Int J Obes 40:844-851.
62. Croxford AL, Lanzinger M, Hartmann FJ, Schreiner B, Mair F, Pelczar P, Clausen BE, Jung S, Greter M, and Becher B (2015) The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity 43: 502-514.
63. Davis KE, Carstens EJ, Irani BG, Gent LM, Hahner LM, and Clegg DJ (2014) Sexually dimorphic role of G protein-coupled estrogen receptor (GPER) in modulating energy homeostasis. Horm Behav 66:196-207.
64. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749-757.
65. De A and DiMarchi RD (2010) Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. Biopolymers 94:448-456.
66. Defossa E and Wagner M (2014) Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett 24:2991-3000.
67. Defronzo RA (2009) Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773-795.
68. Dehvari N, Hutchinson DS, Nevzorova J, Dallner OS, Sato M, Kocan M, Merlin J, Evans BA, Summers RJ, and Bengtsson T (2012) b(2)-Adrenoceptors increase translocation of GLUT4 via GPCR kinase sites in the receptor C-terminal tail. Br J Pharmacol 165:1442-1456.
69. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, et al. (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5:421-427.
70. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA, et al. (2011) Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 127:358-366.
71. De Toni L, Guidolin D, De Filippis V, Tescari S, Strapazzon G, Santa Rocca M, Ferlin A, Plebani M, and Foresta C (2016) Osteocalcin and sex hormone binding globulin compete on a specific binding site of GPRC6A. Endocrinology 157:4473-4486.
72. Dezaki K, Sone H, and Yada T (2008) Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 118:239-249.
73. de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, and Schall TJ; CCX140-B Diabetic Nephropathy Study Group (2015) The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 3:687-696.
74. Di Nisio A, Rocca MS, Fadini GP, De Toni L, Marcuzzo G, Marescotti MC, Sanna M, Plebani M, Vettor R, Avogaro A, et al. (2017) The rs2274911 polymorphism in GPRC6A gene is associated with insulin resistance in normal weight and obese subjects. Clin Endocrinol (Oxf) 86:185-191.
75. Dobbins R, Byerly R, Gaddy R, Gao F, Mahar K, Napolitano A, Ambery P, and Le Monnier de Gouville AC (2015) GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes: a randomised trial. Eur J Pharmacol 755:95-101.
76. Dobbins RL, Shearn SP, Byerly RL, Gao FF, Mahar KM, Napolitano A, Nachbaur GJ, and Le Monnier de Gouville AC (2013) GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab 15:1013-1021.
77. Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13:465-476.
78. Donath MY and Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107.
79. Donnelly D (2012) The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 166:27-41.
80. Douglass JD, Dorfman MD, and Thaler JP (2017) Glia: silent partners in energy homeostasis and obesity pathogenesis. Diabetologia 60:226-236.
81. Du Toit E, Browne L, Irving-Rodgers H, Massa HM, Fozzard N, Jennings MP, and Peak IR (2017) Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets. Eur J Nutr 36:485.
82. Du X, Kim Y-J, Lai S, Chen X, Lizarzaburu M, Turcotte S, Fu Z, Liu Q, Zhang Y, Motani A, et al. (2012) Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes. Bioorg Med Chem Lett 22:6218-6223.
83. Dungan KM, Povedano ST, Forst T, González JGG, Atisso C, Sealls W, and Fahrbach JL (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 384:1349-1357.
84. Emilsson V, Summers RJ, Hamilton S, Liu YL, and Cawthorne MA (1998) The effects of the beta3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem Biophys Res Commun 252:450-454.
85. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, and Strosberg AD (1989) Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118-1121.
86. Engel KMY, Schröck K, Teupser D, Holdt LM, Tönjes A, Kern M, Dietrich K, Kovacs P, Krügel U, Scheidt HA, et al. (2011) Reduced food intake and body weight in mice deficient for the G protein-coupled receptor GPR82. PLoS One 6:e29400.
87. Eriksson P, Dahlman I, Rydén M, Hoffstedt J, and Arner P (2004) Relationship between beta-2 adrenoceptor gene haplotypes and adipocyte lipolysis in women. Int J Obes Relat Metab Disord 28:185-190.
88. Esser N, Legrand-Poels S, Piette J, Scheen AJ, and Paquot N (2014) Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 105:141-150.
89. Esser N, Paquot N, and Scheen AJ (2015) Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 24:283-307.
90. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A, and Summers RJ (2011) Quantification of functional selectivity at the human a(1A)-adrenoceptor. Mol Pharmacol 79:298-307.
91. Evans BA, Papaioannou M, Bonazzi VR, and Summers RJ (1996) Expression of beta 3-adrenoceptor mRNA in rat tissues. Br J Pharmacol 117:210-216.
92. Evans BA, Papaioannou M, Hamilton S, and Summers RJ (1999) Alternative splicing generates two isoforms of the beta3-adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol 127:1525-1531.
93. Evans BA, Sato M, Sarwar M, Hutchinson DS, and Summers RJ (2010) Liganddirected signalling at beta-adrenoceptors. Br J Pharmacol 159:1022-1038.
94. Færch K, Johansen NB, Witte DR, Lauritzen T, Jørgensen ME, and Vistisen D (2015) Relationship between insulin resistance and b-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab 100:707-716.
95. Færch K, Witte DR, Tabák AG, Perreault L, Herder C, Brunner EJ, Kivimäki M, and Vistisen D (2013) Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol 1:43-51.
96. Favret S, Binet F, Lapalme E, Leboeuf D, Carbadillo J, Rubic T, Picard E, Mawambo G, Tetreault N, Joyal JS, et al. (2013) Deficiency in the metabolite receptor SUCNR1 (GPR91) leads to outer retinal lesions. Aging (Albany NY) 5:427-444.
97. Flatt PR (2008) Dorothy Hodgkin lecture 2008: gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabet Med 25:759-764.
98. Flechtner-Mors M, Jenkinson CP, Alt A, Biesalski HK, Adler G, and Ditschuneit HH (2004) Sympathetic regulation of glucose uptake by the alpha1-adrenoceptor in human obesity. Obes Res 12:612-620.
99. Flock G, Holland D, Seino Y, and Drucker DJ (2011) GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 152:374-383.
100. Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26:77-82.
101. Fraterrigo G, Fabbrini E, Mittendorfer B, O’Rahilly S, Scherer PE, Patterson BW, and Klein S (2012) Relationship between changes in plasma adiponectin concentration and insulin sensitivity after niacin therapy. Cardiorenal Med 2:211-217.
102. Fricks IP, Maddileti S, Carter RL, Lazarowski ER, Nicholas RA, Jacobson KA, and Harden TK (2008) UDP is a competitive antagonist at the human P2Y14 receptor. J Pharmacol Exp Ther 325:588-594.
103. Galbo T, Perry RJ, Jurczak MJ, Camporez J-PG, Alves TC, Kahn M, Guigni BA, Serr J, Zhang D, Bhanot S, et al. (2013) Saturated and unsaturated fat induce hepatic insulin resistance independently of TLR-4 signaling and ceramide synthesis in vivo. Proc Natl Acad Sci USA 110:12780-12785.
104. Garaulet M, Gómez-Abellán P, Rubio-Sastre P, Madrid JA, Saxena R, and Scheer FAJL (2015) Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans. Metabolism 64: 1650-1657.
105. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, and Orozco-Beltrán D (2013) Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 4:175-194.
106. Gardner J, Wu S, Ling L, Danao J, Li Y, Yeh W-C, Tian H, and Baribault H (2012) Gprotein- coupled receptor GPR21 knockout mice display improved glucose tolerance and increased insulin response. Biochem Biophys Res Commun 418:1-5.
107. Gautam D, Jeon J, Li JH, Han S-J, Hamdan FF, Cui Y, Lu H, Deng C, Gavrilova O, andWess J (2008)Metabolic roles of the M3 muscarinic acetylcholine receptor studied with M3 receptor mutant mice: a review. J Recept Signal Transduct Res 28:93-108.
108. Ghorbani M, Shafiee Ardestani M, Gigloo SH, Cohan RA, Inanlou DN, and Ghorbani P (2012) Anti diabetic effect of CL 316,243 (a b3-adrenergic agonist) by down regulation of tumour necrosis factor (TNF-a) expression. PLoS One 7:e45874.
109. Gloriam DE, Wellendorph P, Johansen LD, Thomsen AR, Phonekeo K, Pedersen DS, and Bräuner-Osborne H (2011) Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. Chem Biol 18:1489-1498.
110. Goldfine AB, Buck JS, Desouza C, Fonseca V, Chen Y-DI, Shoelson SE, Jablonski KA, and Creager MA; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes-Flow-Mediated Dilation) Ancillary Study Team (2013) Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flowmediated dilation (TINSAL-FMD). Diabetes Care 36:4132-4139.
111. Goldfine AB, Fonseca V, and Shoelson SE (2011) Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem 57:162-167.
112. González-Manchón C, Ayuso MS, and Parrilla R (1989) Control of hepatic gluconeogenesis: role of fatty acid oxidation. Arch Biochem Biophys 271:1-9.
113. Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, et al. (2016) Glucagon-like peptide-1 and its class B G protein-coupled receptors: a long march to therapeutic successes. Pharmacol Rev 68:954-1013.
114. Gruden G, Barutta F, Kunos G, and Pacher P (2016) Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol 173:1116-1127.
115. Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, Buist N, Terebetski J, Kelly T, Bugianesi R, et al. (2016) Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7: 1107-1111.
116. Gutierrez DA, Kennedy A, Orr JS, Anderson EK, Webb CD, Gerrald WK, and Hasty AH (2011) Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2-deficient mice delays improvements in insulin sensitivity. Diabetes 60:2820-2829.
117. Gylfe E and Gilon P (2014) Glucose regulation of glucagon secretion. Diabetes Res Clin Pract 103:1-10.
118. Hamdouchi C, Kahl SD, Patel Lewis A, Cardona GR, Zink RW, Chen K, Eessalu TE, Ficorilli JV, Marcelo MC, Otto KA, et al. (2016) The discovery, preclinical, and early clinical development of potent and selective GPR40 agonists for the treatment of type 2 diabetes mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem 59:10891-10916
119. Hansen HS, Rosenkilde MM, Holst JJ, and Schwartz TW (2012) GPR119 as a fat sensor. Trends Pharmacol Sci 33:374-381.
120. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, and Drucker DJ (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117:143-152.
121. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, and Said SI (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 166:4-17.
122. Heit JJ, Karnik SK, and Kim SK (2006) Intrinsic regulators of pancreatic beta-cell proliferation. Annu Rev Cell Dev Biol 22:311-338.
123. Henstridge CM, Balenga NA, Schröder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler JL, Kostenis E, et al. (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160:604-614.
124. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, and Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90-94.
125. Hohenhaus DM, Schaale K, Le Cao KA, Seow V, Iyer A, Fairlie DP, and Sweet MJ (2013) An mRNA atlas of G protein-coupled receptor expression during primary human monocyte/macrophage differentiation and lipopolysaccharide-mediated activation identifies targetable candidate regulators of inflammation. Immunobiology 218:1345-1353.
126. Hotamisligil GS (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140:900-917.
127. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, and Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415.
128. Hotamisligil GS, Shargill NS, and Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91.
129. Houthuijzen JM (2016) For better or worse: FFAR1 and FFAR4 signaling in cancer and diabetes. Mol Pharmacol 90:738-743.
130. Huang C, Yuan L, and Cao S (2015a) Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets. Int J Mol Med 36:173-185.
131. Huang X-P, Karpiak J, Kroeze WK, Zhu H, Chen X, Moy SS, Saddoris KA, Nikolova VD, Farrell MS, Wang S, et al. (2015b) Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 527:477-483.
132. Hui H, Farilla L, Merkel P, and Perfetti R (2002) The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146:863-869.
133. Hunt DG, Ding Z, and Ivy JL (2002) Clenbuterol prevents epinephrine from antagonizing insulin-stimulated muscle glucose uptake. J Appl Physiol (1985) 92: 1285-1292.
134. Husted AS, Trauelsen M, Rudenko O, Hjorth SA, and Schwartz TW (2017) GPCRmediated signaling of metabolites. Cell Metab 25:777-796.
135. Hutchinson DS and Bengtsson T (2006) AMP-activated protein kinase activation by adrenoceptors in L6 skeletal muscle cells: mediation by alpha1-adrenoceptors causing glucose uptake. Diabetes 55:682-690.
136. Iepsen EW, Torekov SS, and Holst JJ (2015) Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther 13:753-767.
137. Ikeda M, Tsuji H, Nakamura S, Ichiyama A, Nishizuka Y, and Hayaishi O (1965) Studies on the biosynthesis of nicotinamide adenine dinucleotide. II. A role of picolinic carboxylase in the biosynthese of nicotinamide adenine dinucelotide from tryptophan in mammals. J Biol Chem 240:1395-1401.
138. Im D-S (2016) Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages. Eur J Pharmacol 785:36-43.
139. Inoue D, Tsujimoto G, and Kimura I (2014) Regulation of energy homeostasis by GPR41. Front Endocrinol (Lausanne) 5:81.
140. Iqbal J, Walsh MT, Hammad SM, and Hussain MM (2017) Sphingolipids and lipoproteins in health and metabolic disorders. Trends Endocrinol Metab 28:506-518
141. Jacobsen SE, Nørskov-Lauritsen L, Thomsen AR, Smajilovic S, Wellendorph P, Larsson NH, Lehmann A, Bhatia VK, and Bräuner-Osborne H (2013) Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor. J Pharmacol Exp Ther 347:298-309.
142. Jaswal JS, Keung W, Wang W, Ussher JR, and Lopaschuk GD (2011) Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333-1350.
143. Jazayeri A, Rappas M, Brown AJH, Kean J, Errey JC, Robertson NJ, Fiez-Vandal C, Andrews SP, Congreve M, Bortolato A, et al. (2017) Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature 546:254-258.
144. Jensen BC, O’Connell TD, and Simpson PC (2011) Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol 51:518-528.
145. Jensen L, Helleberg H, Roffel A, van Lier JJ, Bjørnsdottir I, Pedersen PJ, Rowe E, Derving Karsbøl J, and Pedersen ML (2017) Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci 104:31-41.
146. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, and Zlotos DP (2016) Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 173:2702-2725.
147. Johansson H, Boesgaard MW, Nørskov-Lauritsen L, Larsen I, Kuhne S, Gloriam DE, Bräuner-Osborne H, and Sejer Pedersen D (2015) Selective allosteric antagonists for the G protein-coupled receptor GPRC6A based on the 2-phenylindole privileged structure scaffold. J Med Chem 58:8938-8951.
148. Jørgensen S, Have CT, Underwood CR, Johansen LD, Wellendorph P, Gjesing AP, Jørgensen CV, Quan S, Rui G, Inoue A, et al. (2017) Genetic variations in the human G protein-coupled receptor class C, group 6, member A (GPRC6A) control cell surface expression and function. J Biol Chem 292:1524-1534.
149. Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, et al. (2014) Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proc Natl Acad Sci USA 111:E5420-E5428.
150. Kakarala KK and Jamil K (2014) Sequence-structure based phylogeny of GPCR class A rhodopsin receptors. Mol Phylogenet Evol 74:66-96.
151. Kalupahana NS, Moustaid-Moussa N, and Claycombe KJ (2012) Immunity as a link between obesity and insulin resistance. Mol Aspects Med 33:26-34.
152. Kang S-U (2013) GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov Today 18:1309-1315.
153. Kawano Y, Nakae J, Watanabe N, Kikuchi T, Tateya S, Tamori Y, Kaneko M, Abe T, Onodera M, and Itoh H (2016) Colonic pro-inflammatory macrophages cause insulin resistance in an intestinal Ccl2/Ccr2-dependent manner. Cell Metab 24: 295-310.
154. Kieffer TJ, Heller RS, Unson CG, Weir GC, and Habener JF (1996) Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137:5119-5125.
155. Kim J, Chung K, Choi C, Beloor J, Ullah I, Kim N, Lee KY, Lee SK, and Kumar P (2016) Silencing CCR2 in macrophages alleviates adipose tissue inflammation and the associated metabolic syndrome in dietary obese mice. Mol Ther Nucleic Acids 5:e280.
156. Kim N, Lee JO, Lee HJ, Kim HI, Kim JK, Lee YW, Lee SK, Kim SJ, Park SH, and Kim HS (2015) Endogenous ligand for GPR120, docosahexaenoic acid, exerts benign metabolic effects on the skeletal muscles via AMP-activated protein kinase pathway. J Biol Chem 290:20438-20447.
157. Kim YJ, Sano T, Nabetani T, Asano Y, and Hirabayashi Y (2012) GPRC5B activates obesity-associated inflammatory signaling in adipocytes. Sci Signal 5(251):ra85.
158. Kimple ME, Keller MP, Rabaglia MR, Pasker RL, Neuman JC, Truchan NA, Brar HK, and Attie AD (2013) Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion. Diabetes 62:1904-1912.
159. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, et al. (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4:1829.
160. Konno Y, Ueki S, Takeda M, Kobayashi Y, Tamaki M, Moritoki Y, Oyamada H, Itoga M, Kayaba H, Omokawa A, et al. (2015) Functional analysis of free fatty acid receptor GPR120 in human eosinophils: implications in metabolic homeostasis. PLoS One 10:e0120386.
161. Koole C, Savage EE, Christopoulos A, Miller LJ, Sexton PM, and Wootten D (2013) Minireview: signal bias, allosterism, and polymorphic variation at the GLP-1R: implications for drug discovery. Mol Endocrinol 27:1234-1244.
162. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, Miller LJ, Summers RJ, Christopoulos A, and Sexton PM (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78:456-465.
163. Kraakman MJ, Murphy AJ, Jandeleit-Dahm K, and Kammoun HL (2014) Macrophage polarization in obesity and type 2 diabetes: weighing down our understanding of macrophage function. Front Immunol 5:470.
164. Krieger J-P, Arnold M, Pettersen KG, Lossel P, Langhans W, and Lee SJ (2016) Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes 65:34-43.
165. Krinninger P, Ensenauer R, Ehlers K, Rauh K, Stoll J, Krauss-Etschmann S, Hauner H, and Laumen H (2014) Peripheral monocytes of obese women display increased chemokine receptor expression and migration capacity. J Clin Endocrinol Metab 99:2500-2509.
166. Ku GM, Pappalardo Z, Luo CC, German MS, and McManus MT (2012) An siRNA screen in pancreatic beta cells reveals a role for Gpr27 in insulin production. PLoS Genet 8:e1002449.
167. Kumar R, Balhuizen A, Amisten S, Lundquist I, and Salehi A (2011) Insulinotropic and antidiabetic effects of 17b-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 152:2568-2579.
168. Kurabayashi N, Nguyen MD, and Sanada K (2013) The G protein-coupled receptor GPRC5B contributes to neurogenesis in the developing mouse neocortex. Development 140:4335-4346.
169. Kusminski CM, Bickel PE, and Scherer PE (2016) Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov 15:639-660.
170. Lafontan M, Piazza PV, and Girard J (2007) Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 33:85-95.
171. Lane JM, Chang A-M, Bjonnes AC, Aeschbach D, Anderson C, Cade BE, Cain SW, Czeisler CA, Gharib SA, Gooley JJ, et al. (2016) Impact of common diabetes risk variant in MTNR1B on sleep, circadian, and melatonin physiology. Diabetes 65: 1741-1751.
172. Lauffer LM, Iakoubov R, and Brubaker PL (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58:1058-1066.
173. Lee B-C and Lee J (2014) Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta 1842:446-462.
174. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456-469.
175. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, Jaeckel P, Ge H, Wang Y, Jiao X, et al. (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol 74: 1599-1609.
176. Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, Chou HL, Hashiguchi T, Plato C, Poulin D, et al. (2016) Antifibrotic effects of the dual CCR2/ CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One 11:e0158156.
177. Leonard S, Kinsella GK, Benetti E, and Findlay JBC (2016) Regulating the effects of GPR21, a novel target for type 2 diabetes. Sci Rep 6:27002.
178. Li A, Li Y, and Du L (2015a) Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research. Future Med Chem 7:1457-1468.
179. Li P, Oh DY, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, Johnson A, Chung H, Maris M, Ofrecio JM, et al. (2015b) LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med 21: 239-247.
180. Li X, Zhong K, Guo Z, Zhong D, and Chen X (2015c) Fasiglifam (TAK-875) inhibits hepatobiliary transporters: a possible factor contributing to fasiglifam-induced liver injury. Drug Metab Dispos 43:1751-1759.
181. Liggett SB (2009) alpha2A-adrenergic receptors in the genetics, pathogenesis, and treatment of type 2 diabetes. Sci Transl Med 1:12ps15.
182. Limbird LE (1988) Receptors linked to inhibition of adenylate cyclase: additional signaling mechanisms. FASEB J 2:2686-2695.
183. Lin DCH, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, Tran T, Dransfield PJ, Brown SP, Houze J, et al. (2012) Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 82:843-859.
184. Lin Y and Sun Z (2010) Current views on type 2 diabetes. J Endocrinol 204:1-11.
185. Littlewood-Evans A, Sarret S, Apfel V, Loesle P, Dawson J, Zhang J, Muller A, Tigani B, Kneuer R, Patel S, et al. (2016) GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med 213:1655-1662.
186. Liu B, Song S, Jones PM, and Persaud SJ (2015a) GPR55: from orphan to metabolic regulator? Pharmacol Ther 145:35-42.
187. Liu HD, Wang WB, Xu ZG, Liu CH, He DF, Du LP, Li MY, Yu X, and Sun JP (2015b) FFA4 receptor (GPR120): a hot target for the development of anti-diabetic therapies. Eur J Pharmacol 763 (Pt B):160-168.
188. Liu J, Ibi D, Taniguchi K, Lee J, Herrema H, Akosman B, Mucka P, SalazarHernandez MA, Uyar MF, Park SW, et al. (2016) Inflammation improves glucose homeostasis through IKKb-XBP1s interaction. Cell 167:1052-1066.e18.
189. Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, Kar NF, Zhu Y, Garfunkle J, Kang L, et al. (2015c) Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett 6:936-941.
190. Lizarzaburu M, Turcotte S, Du X, Duquette J, Fu A, Houze J, Li L, Liu J, Murakoshi M, Oda K, et al. (2012) Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus. Bioorg Med Chem Lett 22:5942-5947.
191. Lyssenko V, Nagorny CLF, Erdos MR, Wierup N, Jonsson A, Spégel P, Bugliani M, Saxena R, Fex M, Pulizzi N, et al. (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82-88.
192. Mackenzie AE, Lappin JE, Taylor DL, Nicklin SA, and Milligan G (2011) GPR35 as a novel therapeutic target. Front Endocrinol (Lausanne) 2:68.
193. Madeddu S, Woods TA, Mukherjee P, Sturdevant D, Butchi NB, and Peterson KE (2015) Identification of glial activation markers by comparison of transcriptome changes between astrocytes and microglia following innate immune stimulation. PLoS One 10:e0127336.
194. Mancini AD and Poitout V (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 24:398-407.
195. Mancini AD and Poitout V (2015) GPR40 agonists for the treatment of type 2 diabetes: life after ‘taking’ a hit. Diabetes Obes Metab 17:622-629.
196. Maravillas-Montero JL, Burkhardt AM, Hevezi PA, Carnevale CD, Smit MJ, and Zlotnik A (2015) Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. J Immunol 194:29-33.
197. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al.; SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834-1844.
198. Mårtensson UEA, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, Wendt A, Andersson N, Hellstrand P, Grände PO, et al. (2009) Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150:687-698.
199. Mazzola N (2012) Review of current and emerging therapies in type 2 diabetes mellitus. Am J Manag Care 18(1 Suppl):S17-S26.
200. McCreath KJ, Espada S, Gálvez BG, Benito M, de Molina A, Sepúlveda P, and Cervera AM (2015) Targeted disruption of the SUCNR1 metabolic receptor leads to dichotomous effects on obesity. Diabetes 64:1154-1167.
201. McKenzie CI, Mackay CR, and Macia L (2015) GPR43: a prototypic metabolite sensor linking metabolic and inflammatory diseases. Trends Endocrinol Metab 26:511-512.
202. McKillop AM, Moran BM, Abdel-Wahab YHA, and Flatt PR (2013) Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br J Pharmacol 170:978-990.
203. McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, and Forman JP (2013) Melatonin secretion and the incidence of type 2 diabetes. JAMA 309:1388-1396.
204. Meadows A, Lee JH, Wu C-S, Wei Q, Pradhan G, Yafi M, Lu HC, and Sun Y (2015) Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. Int J Obes 40:417-424
205. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728-742.
206. Meister J, Le Duc D, Ricken A, Burkhardt R, Thiery J, Pfannkuche H, Polte T, Grosse J, Schöneberg T, and Schulz A (2014) The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice. J Biol Chem 289: 23353-23366.
207. Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Więcek A, and Haller H; Emapticap Study Group (2017) C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 32:307-315.
208. Michel MC and Gravas S (2016) Safety and tolerability of b3-adrenoceptor agonists in the treatment of overactive bladder syndrome: insight from transcriptosome and experimental studies. Expert Opin Drug Saf 15:647-657.
209. Michelotti GA, Machado MV, and Diehl AM (2013) NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10:656-665.
210. Milligan G (2011) Orthologue selectivity and ligand bias: translating the pharmacology of GPR35. Trends Pharmacol Sci 32:317-325.
211. Milligan G, Shimpukade B, Ulven T, and Hudson BD (2017) Complex pharmacology of free fatty acid receptors. Chem Rev 117:67-110.
212. Milligan G, Stoddart LA, and Smith NJ (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158: 146-153.
213. Mittermayer F, Caveney E, De Oliveira C, Gourgiotis L, Puri M, Tai LJ, and Turner JR (2015) Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development. Curr Diabetes Rev 11:17-31.
214. Mizokami A, Yasutake Y, Gao J, Matsuda M, Takahashi I, Takeuchi H, and Hirata M (2013) Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One 8:e57375.
215. Moody TW, Ito T, Osefo N, and Jensen RT (2011) VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr Opin Endocrinol Diabetes Obes 18:61-67.
216. Morino K, Petersen KF, and Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl 2):S9-S15.
217. Mueckler MM (1992) The molecular biology of mammalian glucose transporters. Curr Opin Nephrol Hypertens 1:12-20.
218. Müller MM, Lehmann R, Klassert TE, Reifenstein S, Conrad T, Moore C, Kuhn A, Behnert A, Guthke R, Driesch D, et al. (2017) Global analysis of glycoproteins identifies markers of endotoxin tolerant monocytes and GPR84 as a modulator of TNFa expression. Sci Rep 7:838.
219. Murakoshi M, Kuwabara H, Nagasaki M, Xiong YM, Reagan JD, Maeda H, and Nara F (2016) Discovery and pharmacological effects of a novel GPR142 antagonist. J Recept Signal Transduct Res 37:290-296.
220. Nagasaki H, Kondo T, Fuchigami M, Hashimoto H, Sugimura Y, Ozaki N, Arima H, Ota A, Oiso Y, and Hamada Y (2012) Inflammatory changes in adipose tissue enhance expression of GPR84, a medium-chain fatty acid receptor: TNFa enhances GPR84 expression in adipocytes. FEBS Lett 586:368-372.
221. Nam DH, Lee MH, Kim JE, Song HK, Kang YS, Lee JE, Kim HW, Cha JJ, Hyun YY, Kim SH, et al. (2012) Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Endocrinology 153:1387-1396.
222. Nedergaard J, Bengtsson T, and Cannon B (2007) Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 293: E444-E452.
223. Nedergaard J and Cannon B (2014) The browning of white adipose tissue: some burning issues. Cell Metab 20:396-407.
224. Németh B, Doczi J, Csete D, Kacso G, Ravasz D, Adams D, Kiss G, Nagy AM, Horvath G, Tretter L, et al. (2016) Abolition of mitochondrial substrate-level phosphorylation by itaconic acid produced by LPS-induced Irg1 expression in cells of murine macrophage lineage. FASEB J 30:286-300.
225. Neuman JC and Kimple ME (2013) The EP3 receptor: exploring a new target for type 2 diabetes therapeutics. J Endocrinol Diabetes Obes 1:1002.
226. Neuman JC, Schaid MD, Brill AL, Fenske RJ, Kibbe CR, Fontaine DA, Sdao SM, Brar HK, Connors KM, Wienkes HN, et al. (2017) Enriching islet phospholipids with eicosapentaenoic acid reduces prostaglandin E2 signaling and enhances diabetic b-cell function. Diabetes 66:1572-1585.
227. Nevzorova J, Bengtsson T, Evans BA, and Summers RJ (2002) Characterization of the beta-adrenoceptor subtype involved in mediation of glucose transport in L6 cells. Br J Pharmacol 137:9-18.
228. Nevzorova J, Evans BA, Bengtsson T, and Summers RJ (2006) Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol 147:446-454.
229. Nøhr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, Sichlau RM, Grunddal KV, Poulsen SS, Han S, et al. (2013) GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154:3552-3564.
230. Nolte WM, Fortin J-P, Stevens BD, Aspnes GE, Griffith DA, Hoth LR, Ruggeri RB, Mathiowetz AM, Limberakis C, Hepworth D, et al. (2014) A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat Chem Biol 10:629-631.
231. Nunez DJ, Bush MA, Collins DA, McMullen SL, Gillmor D, Apseloff G, Atiee G, Corsino L, Morrow L, and Feldman PL (2014) Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS One 9:e92494.
232. O’Connell TD, Jensen BC, Baker AJ, and Simpson PC (2013) Cardiac alpha1- adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev 66:308-333.
233. Odori S, Hosoda K, Tomita T, Fujikura J, Kusakabe T, Kawaguchi Y, Doi R, Takaori K, Ebihara K, Sakai Y, et al. (2013) GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism 62:70-78.
234. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, and Olefsky JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687-698.
235. Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, Cox JM, et al. (2014) A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20:942-947.
236. Olefsky JM and Glass CK (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219-246.
237. Ortiz-Alonso FJ, Herman WH, Gertz BJ, Williams VC, Smith MJ, and Halter JB (1991) Effect of an oral alpha 2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulin-dependent diabetes mellitus. Metabolism 40:1160-1167.
238. Osborn O, Oh DY, McNelis J, Sanchez-Alavez M, Talukdar S, Lu M, Li P, Thiede L, Morinaga H, Kim JJ, et al. (2012) G protein-coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice. J Clin Invest 122:2444-2453.
239. Osborn O and Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18:363-374.
240. Ostenson CG, Pigon J, Doxey JC, and Efendic S (1988) Alpha 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with noninsulin-dependent diabetes. J Clin Endocrinol Metab 67: 1054-1059.
241. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, et al. (2008) G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149: 4846-4856.
242. Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, Srinivas P, Chamouni A, Lugani F, Lejeune H, et al. (2013) Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J Clin Invest 123:2421-2433.
243. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, et al. (2011) Endocrine regulation of male fertility by the skeleton. Cell 144:796-809.
244. Panaro BL, Flock GB, Campbell JE, Beaudry JL, Cao X, and Drucker DJ (2017) b-Cell inactivation of Gpr119 unmasks incretin dependence of GPR119-mediated glucoregulation. Diabetes 66:1626-1635.
245. Perley MJ and Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 46:1954-1962.
246. Pi M, Chen L, Huang MZ, Zhu W, Ringhofer B, Luo J, Christenson L, Li B, Zhang J, Jackson PD, et al. (2008) GPRC6A null mice exhibit osteopenia, feminization and metabolic syndrome. PLoS One 3:e3858.
247. Pi M, Kapoor K, Ye R, Nishimoto SK, Smith JC, Baudry J, and Quarles LD (2016) Evidence for osteocalcin binding and activation of GPRC6A in b-cells. Endocrinology 157:1866-1880.
248. Pi M and Quarles LD (2012) GPRC6A regulates prostate cancer progression. Prostate 72:399-409.
249. Pi M, Wu Y, Lenchik NI, Gerling I, and Quarles LD (2012) GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. Endocrinology 153:4608-4615.
250. Pi M, Wu Y, and Quarles LD (2011) GPRC6A mediates responses to osteocalcin in b-cells in vitro and pancreas in vivo. J Bone Miner Res 26:1680-1683.
251. Piascik MT and Perez DM (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403-410.
252. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, and Judd RL (2009) Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab 296:E549-E558.
253. Popa SM, Clifton DK, and Steiner RA (2008) The role of kisspeptins and GPR54 in the neuroendocrine regulation of reproduction. Annu Rev Physiol 70:213-238.
254. Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, et al.; HARMONY 7 Study Group (2014) Onceweekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2:289-297.
255. Prentki M and Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812.
256. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, Manning AK, Jackson AU, Aulchenko Y, et al. (2009) Variants in MTNR1B influence fasting glucose levels. Nat Genet 41:77-81.
257. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, and Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15.
258. Regard JB, Sato IT, and Coughlin SR (2008) Anatomical profiling of G proteincoupled receptor expression. Cell 135:561-571.
259. Renström F, Koivula RW, Varga TV, Hallmans G, Mulder H, Florez JC, Hu FB, and Franks PW (2015) Season-dependent associations of circadian rhythmregulating loci (CRY1, CRY2 and MTNR1B) and glucose homeostasis: the GLACIER Study. Diabetologia 58:997-1005.
260. Ritter K, Buning C, Halland N, Pöverlein C, and Schwink L (2016) G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges. J Med Chem 59:3579-3592.
261. Robbins MJ, Michalovich D, Hill J, Calver AR, Medhurst AD, Gloger I, Sims M, Middlemiss DN, and Pangalos MN (2000) Molecular cloning and characterization of two novel retinoic acid-inducible orphan G-protein-coupled receptors (GPRC5B and GPRC5C). Genomics 67:8-18.
262. Rohrbach K, Thomas MA, Glick S, Fung EN, Wang V, Watson L, Gregory P, Antel J, and Pelleymounter MA (2012) Ibipinabant attenuates b-cell loss in male Zucker diabetic fatty rats independently of its effects on body weight. Diabetes Obes Metab 14:555-564.
263. Rönn T, Wen J, Yang Z, Lu B, Du Y, Groop L, Hu R, and Ling C (2009) A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 52: 830-833.
264. Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ, Nagaraj V, Reinbothe TM, Tuncel J, Eliasson L, et al. (2010) Overexpression of alpha2Aadrenergic receptors contributes to type 2 diabetes. Science 327:217-220.
265. Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156-163.
266. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun 3:1329.
267. Roth Flach RJ, Matevossian A, Akie TE, Negrin KA, Paul MT, and Czech MP (2013) b3-Adrenergic receptor stimulation induces E-selectin-mediated adipose tissue inflammation. J Biol Chem 288:2882-2892.
268. Roth JD, Erickson MR, Chen S, and Parkes DG (2012) GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol 166:121-136.
269. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-Perrig N, Schwärzler C, Junt T, Voshol H, Meingassner JG, et al. (2008) Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol 9: 1261-1269.
270. Rueda P, Harley E, Lu Y, Stewart GD, Fabb S, Diepenhorst N, Cremers B, Rouillon MH, Wehrle I, Geant A, et al. (2016) Murine GPRC6A mediates cellular responses to L-amino acids, but not osteocalcin variants. PLoS One 11:e0146846.
271. Salcedo I, Tweedie D, Li Y, and Greig NH (2012) Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 166:1586-1599.
272. Samuel VT and Shulman GI (2012) Mechanisms for insulin resistance: common threads and missing links. Cell 148:852-871.
273. Sato M, Dehvari N, Oberg AI, Dallner OS, Sandström AL, Olsen JM, Csikasz RI, Summers RJ, Hutchinson DS, and Bengtsson T (2014) Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes 63:4115-4129.
274. Scheen AJ (2007) Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21:535-553.
275. Scheer FAJL, Hilton MF, Mantzoros CS, and Shea SA (2009) Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 106:4453-4458.
276. Schmidt J, Smith NJ, Christiansen E, Tikhonova IG, Grundmann M, Hudson BD, Ward RJ, Drewke C, Milligan G, Kostenis E, et al. (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem 286: 10628-10640.
277. Schroder K, Zhou R, and Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327:296-300.
278. Secher A, Jelsing J, Baquero AF, Hecksher-Sørensen J, Cowley MA, Dalbøge LS, Hansen G, Grove KL, Pyke C, Raun K, et al. (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124: 4473-4488.
279. Sennitt MV, Arch JR, Levy AL, Simson DL, Smith SA, and Cawthorne MA (1985) Anti-hyperglycaemic action of BRL 26830, a novel beta-adrenoceptor agonist, in mice and rats. Biochem Pharmacol 34:1279-1285.
280. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, and Prossnitz ER (2013) GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology 154:4136-4145.
281. Sharma G, Mauvais-Jarvis F, and Prossnitz ER (2017) Roles of G protein-coupled estrogen receptor GPER in metabolic regulation. J Steroid Biochem Mol Biol DOI: 10.1016/j.jsbmb.2017.02.012 [published ahead of print].
282. Shehata MA, Christensen HB, Isberg V, Pedersen DS, Bender A, Bräuner-Osborne H, Shehata MA, Pedersen DS, and Gloriam DE (2015) Identification of the first surrogate agonists for the G protein-coupled receptor GPR132. RSC Advances 5: 48551-48557.
283. Shi C and Pamer EG (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11:762-774.
284. Shi T, Papay RS, and Perez DM (2016) a1A-Adrenergic receptor prevents cardiac ischemic damage through PKCd/GLUT1/4-mediated glucose uptake. J Recept Signal Transduct Res 36:261-270.
285. Shore DM and Reggio PH (2015) The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol 6:69.
286. Shu CJ, Benoist C, and Mathis D (2012) The immune system’s involvement in obesity-driven type 2 diabetes. Semin Immunol 24:436-442.
287. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176.
288. Simcocks AC, O’Keefe L, Jenkin KA, Mathai ML, Hryciw DH, and McAinch AJ (2014) A potential role for GPR55 in the regulation of energy homeostasis. Drug Discov Today 19:1145-1151.
289. Sina C, Gavrilova O, Förster M, Till A, Derer S, Hildebrand F, Raabe B, Chalaris A, Scheller J, Rehmann A, et al. (2009) G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol 183:7514-7522.
290. Sisley S, Gutierrez-Aguilar R, Scott M, D’Alessio DA, Sandoval DA, and Seeley RJ (2014) Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest 124:2456-2463.
291. Smajilovic S, Clemmensen C, Johansen LD, Wellendorph P, Holst JJ, Thams PG, Ogo E, and Bräuner-Osborne H (2013) The L-a-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in L-arginine-induced insulin release. Amino Acids 44:383-390.
292. Smith LL, Mosley JF II, Parke C, Brown J, Barris LS, and Phan LD (2016) Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist. P&T 41:357-360.
293. Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, Morris JC, Tränkle C, Tikhonova IG, Adams DR, et al. (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 80:163-173.
294. Song G, Yang D, Wang Y, de Graaf C, Zhou Q, Jiang S, Liu K, Cai X, Dai A, Lin G, et al. (2017) Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators. Nature 546:312-315.
295. Soni A, Amisten S, Rorsman P, and Salehi A (2013) GPRC5B a putative glutamatereceptor candidate is negative modulator of insulin secretion. Biochem Biophys Res Commun 441:643-648.
296. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU, Lango Allen H, Lindgren CM, Luan J, Mägi R, et al.; MAGIC;; Procardis Consortium (2010) Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 42:937-948.
297. Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, and Haribabu B (2011) Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol 187:1942-1949.
298. Sprecher D, Maxwell M, Goodman J, White B, Tang CMM, Boullay V, and de Gouville AC (2015) Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist. Eur J Pharmacol 756:1-7.
299. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, Nguyen J, et al. (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513:124-127.
300. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sörhede Winzell M, Hammar M, Xu X, Smith DM, and Morgan NG (2014) GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. Diabetologia 57:1182-1191.
301. Sullivan T, Miao Z, Dairaghi DJ, Krasinski A, Wang Y, Zhao BN, Baumgart T, Ertl LS, Pennell A, Seitz L, et al. (2013b) CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice. Am J Physiol Renal Physiol 305:F1288-F1297.
302. Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, et al. (2013a) Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes. Metabolism 62:1623-1632.
303. Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, Maeda H, Komai T, and Oda T (2013) Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem 288:10684-10691.
304. Tager AM and Luster AD (2003) BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 69:123-134.
305. Talukdar S, Olefsky JM, and Osborn O (2011) Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases. Trends Pharmacol Sci 32:543-550.
306. Tang C, Ahmed K, Gille A, Lu S, Gröne HJ, Tunaru S, and Offermanns S (2015) Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med 21:173-177.
307. Tanti J-F, Ceppo F, Jager J, and Berthou F (2013) Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne) 3:181.
308. Thorburn AN, Macia L, and Mackay CR (2014) Diet, metabolites, and “westernlifestyle” inflammatory diseases. Immunity 40:833-842.
309. Tian L, Gao J, Weng G, Yi H, Tian B, O’Brien TD, and Guo Z (2011) Comparison of exendin-4 on beta-cell replication in mouse and human islet grafts. Transpl Int 24: 856-864.
310. Tian R and Abel ED (2001) Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103:2961-2966.
311. Toda N, Hao X, Ogawa Y, Oda K, Yu M, Fu Z, Chen Y, Kim Y, Lizarzaburu M, Lively S, et al. (2013) Potent and orally bioavailable GPR142 agonists as novel insulin secretagogues for the treatment of type 2 diabetes. ACS Med Chem Lett 4:790-794.
312. Trujillo JM, Nuffer W, and Ellis SL (2015) GLP-1 receptor agonists: a review of headto- head clinical studies. Ther Adv Endocrinol Metab 6:19-28.
313. Tsou C-L, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, and Charo IF (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117: 902-909.
314. Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, Isomaa B, Östman B, Söderström J, Pesonen AK, et al. (2016) Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab 23:1067-1077.
315. Ulven T (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 3:111.
316. Ulven T and Christiansen E (2015) Dietary fatty acids and their potential for controlling metabolic diseases through activation of FFA4/GPR120. Annu Rev Nutr 35: 239-263.
317. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, and Diamant M (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221:T1-T16.
318. Van den Bossche J, O’Neill LA, and Menon D (2017) Macrophage immunometabolism: where are we (going)? Trends Immunol 38:395-406.
319. van Diepen JA, Robben JH, Hooiveld GJ, Carmone C, Alsady M, Boutens L, Bekkenkamp-Grovenstein M, Hijmans A, Engelke UFH, Wevers RA, et al. (2017) SUCNR1-mediated chemotaxis of macrophages aggravates obesity-induced inflammation and diabetes. Diabetologia 60:1304-1313.
320. Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, and Dixit VD (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17:179-188.
321. Vangoitsenhoven R, Mathieu C, and Van der Schueren B (2012) GLP1 and cancer: friend or foe? Endocr Relat Cancer 19:F77-F88.
322. Velez M, Peterson EL, Wells K, Swadia T, Sabbah HN, Williams LK, and Lanfear DE (2015) Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes. J Card Fail 21:2-8.
323. Vilsbøll T (2009) The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 11 (Suppl 3):11-18.
324. Vinolo MAR, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly Y M, Stephens L, Hawkins PT, and Curi R (2011) SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 6:e21205.
325. Wanders D and Judd RL (2011) Future of GPR109A agonists in the treatment of dyslipidaemia. Diabetes Obes Metab 13:685-691.
326. Wang A, Luo J, Moore W, Alkhalidy H, Wu L, Zhang J, Zhen W, Wang Y, Clegg DJ, Bin Xu, et al. (2016) GPR30 regulates diet-induced adiposity in female mice and adipogenesis in vitro. Sci Rep 6:34302.
327. Wang J, Carrillo JJ, and Lin HV (2016a) GPR142 agonists stimulate glucosedependent insulin secretion via Gq-dependent signaling. PLoS One 11:e0154452.
328. Wang J, Wu X, Simonavicius N, Tian H, and Ling L (2006) Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 281: 34457-34464.
329. Wang J, Zheng P, Baribault H, Chui D, Gundel C, and Veniant M (2016b) GPR21 KO mice demonstrate no resistance to high fat diet induced obesity or improved glucose tolerance. F1000Res 5:36.
330. Wang S, Awad KS, Elinoff JM, Dougherty EJ, Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A, and Danner RL (2015) G protein-coupled receptor 40 (GPR40) and peroxisome proliferator-activated receptor g (PPARg): an integrated two-receptor signaling pathway. J Biol Chem 290:19544-19557.
331. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, and Ferrante AW Jr (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124.
332. Wellendorph P and Bräuner-Osborne H (2009) Molecular basis for amino acid sensing by family C G-protein-coupled receptors. Br J Pharmacol 156:869-884.
333. Wellendorph P, Johansen LD, Jensen AA, Casanova E, Gassmann M, Deprez P, Clément-Lacroix P, Bettler B, and Bräuner-Osborne H (2009) No evidence for a bone phenotype in GPRC6A knockout mice under normal physiological conditions. J Mol Endocrinol 42:215-223.
334. Wiberg S, Hassager C, Schmidt H, Thomsen JH, Frydland M, and Lindholm MG, Høfsten DE, Engstrøm T, Køber L, Møller JE, and Kjaergaard J. (2016) Neuroprotective effects of the glucagon-like peptide-1 analog exenatide after out-ofhospital cardiac arrest clinical perspective. Circulation 134:2115-2124.
335. Wier WG and Morgan KG (2003) Alpha1-adrenergic signaling mechanisms in contraction of resistance arteries. Rev Physiol Biochem Pharmacol 150:91-139.
336. Wilcox G (2005) Insulin and insulin resistance. Clin Biochem Rev 26:19-39.
337. Willard FS, Bueno AB, and Sloop KW (2012) Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res 2012:709893.
338. Williams CA, Shih MF, and Taberner PV (1999) Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A. Br J Pharmacol 128:1586-1592.
339. Williamson RT (1901) On the treatment of glycosuria and diabetes mellitus with sodium salicylate. BMJ 1:760-762.
340. Willis MS, Ilaiwy A, Montgomery MD, Simpson PC, and Jensen BC (2016) The alpha- 1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid and endocannabinoid metabolites associated with inflammation in vivo. Metabolomics 12:155.
341. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, et al.; Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145-154.
342. Wise A, Gearing K, and Rees S (2002) Target validation of G-protein coupled receptors. Drug Discov Today 7:235-246.
343. Wong TP, Chan LKY, and Leung PS (2015) Involvement of the niacin receptor GPR109a in the local control of glucose uptake in small intestine of type 2 diabetic mice. Nutrients 7:7543-7561.
344. Wootten D, Miller LJ, Koole C, Christopoulos A, and Sexton PM (2017) Allostery and biased agonism at class B G protein-coupled receptors. Chem Rev 117:111-138.
345. Wootten D, Reynolds CA, Smith KJ, Mobarec JC, Koole C, Savage EE, Pabreja K, Simms J, Sridhar R, Furness SGB, et al. (2016) The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism. Cell 165:1632-1643.
346. Wree A, Broderick L, Canbay A, Hoffman HM, and Feldstein AE (2013) From NAFLD to NASH to cirrhosis: new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 10:627-636.
347. Wu Q, Wang H, Zhao X, Shi Y, Jin M, Wan B, Xu H, Cheng Y, Ge H, and Zhang Y (2013) Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma. Oncogene 32:5541-5550.
348. Wurtman RJ and Anton-Tay F (1969) The mammalian pineal as a neuroendocrine transducer. Recent Prog Horm Res 25:493-522.
349. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, Song Z, El-Gohary Y, Prasadan K, Shiota C, and Gittes GK (2014) M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci U S A 111:E1211-20.
350. Xu J, Morinaga H, Oh D, Li P, Chen A, Talukdar S, Mamane Y, Mancini JA, Nawrocki AR, Lazarowski E, et al. (2012) GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity. J Immunol 189: 1992-1999.
351. Yalow RS and Berson SA (1960) Immunoassay of endogenous plasma insulin in man. J Clin Invest 39:1157-1175.
352. Yang JW, Kim HS, Im JH, Kim J-W, Jun DW, Lim SC, Lee K, Choi JM, Kim SK, and Kang KW (2016) GPR119: a promising target for nonalcoholic fatty liver disease. FASEB J 30:324-335.
353. Yokomizo T, Izumi T, and Shimizu T (2001) Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 385:231-241.
354. Yu M, Lizarzaburu M, Motani A, Fu Z, Du X, Liu JJ, Jiao X, Lai S, Fan P, Fu A, et al. (2013) Aminopyrazole-phenylalanine based GPR142 agonists: discovery of tool compound and in vivo efficacy studies. ACS Med Chem Lett 4:829-834.
355. Zaccardi F, Htike ZZ, Webb DR, Khunti K, and Davies MJ (2016) Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: a systematic review and network meta-analysis. Ann Intern Med 164:102-113.
356. Zhang H, Sturchler E, Zhu J, Nieto A, Cistrone PA, Xie J, He L, Yea K, Jones T, Turn R, et al. (2015) Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects. Nat Commun 6:8918.
357. Zhang S, Ma Y, Li J, Ma J, Yu B, and Xie X (2014) Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder. Proc Natl Acad Sci USA 111:14571-14576.
358. Zhang Y, Sun B, Feng D, Hu H, Chu M, Qu Q, Tarrasch JT, Li S, Sun Kobilka T, Kobilka BK, et al. (2017) Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature 546:248-253.
359. Zheng Y, Qin L, Zacarías NVO, de Vries H, Han GW, Gustavsson M, Dabros M, Zhao C, Cherney RJ, Carter P, et al. (2016) Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature 540:458-461.
360. Zweemer AJM, Nederpelt I, Vrieling H, Hafith S, Doornbos MLJ, de Vries H, Abt J, Gross R, Stamos D, Saunders J, et al. (2013) Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2. Mol Pharmacol 84:551-561.